US44842L1035

HUTCHMED Announces NMPA Full Approval for ORPATHYS(savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLCHUTCHMED Announces NMPA Full Approval for ORPATHYS(savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Announces NMPA Full Approval for ORPATHYS(savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

January 13, 2025 23:00 ET  | Source: HUTCHMED (China) Limited — Indication expands to include treatment-naïve patients — — The 2021…

2 months ago
HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapyHUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy

HUTCHMEDAnnounces NDA Acceptance in China with Priority Review Status for ORPATHYSand TAGRISSOCombination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFRInhibitorTherapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…

2 months ago
HUTCHMED Announces US$608 million Divestment of Non-Core JointVentureHUTCHMED Announces US$608 million Divestment of Non-Core JointVenture

HUTCHMED Announces US$608 million Divestment of Non-Core JointVenture

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative…

2 months ago
HUTCHMED Announces US$608 million Divestment of Non-Core JointVentureHUTCHMED Announces US$608 million Divestment of Non-Core JointVenture

HUTCHMED Announces US$608 million Divestment of Non-Core JointVenture

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative…

2 months ago
HUTCHMED to Receive Milestone Payment from Takeda following FirstEuropeanReimbursement for FRUZAQLA (fruquintinib)HUTCHMED to Receive Milestone Payment from Takeda following FirstEuropeanReimbursement for FRUZAQLA (fruquintinib)

HUTCHMED to Receive Milestone Payment from Takeda following FirstEuropeanReimbursement for FRUZAQLA (fruquintinib)

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of…

3 months ago
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor TherapyHUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…

3 months ago
HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at CurrentTermsHUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at CurrentTerms

HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at CurrentTerms

November 28, 2024 05:30 ET | Source: HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 28,…

4 months ago